Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response
- PMID: 12074047
- DOI: 10.1097/00002371-200203000-00005
Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response
Abstract
The function of dendritic cells (DCs), antigen-presenting cells that can initiate and regulate cellular and humoral responses, is highly influenced by their level of maturation. Immature DCs may be harmful in anti-tumor immunotherapy, because they can induce immunotolerance rather than immunostimulation. In this study, the authors sought to determine the optimal culture conditions for obtaining fully mature DCs. When DCs were cultured in agonistic anti-CD40 monoclonal antibody-immobilized plates, they showed a higher expression of the maturation marker CD83 than DCs cultured without CD40 ligation or those cultured in medium supplemented with anti-CD40 monoclonal antibody. In addition, when interferon-gamma (IFN-gamma) was added to the medium, additive up-regulation of CD83 expression was observed. These DCs treated with both maturation signals showed a higher secretion of interleukin-12. To evaluate the capacity of antigen presentation, specific cytotoxic T lymphocytes were generated using autologous DC pulsed with a human lymphocyte antigen-A24-restricted peptide epitope derived from carcinoembryonic antigen. Interferon-gamma-secreting CD8+ T cells were analyzed by flow cytometry using the cellular affinity matrix technology. Dendritic cells, matured with CD40 ligation and IFN-gamma, were more efficient at eliciting an antigen-specific T-cell response in vitro than DCs stimulated with anti-CD40 monoclonal antibody or IFN-gamma alone. A cytotoxicity assay using carcinoembryonic antigen-expressing tumor cell lines also showed that DCs matured with both signals were more efficient at inducing cytotoxic T lymphocytes. These results demonstrate that DC culture in an anti-CD40 monoclonal antibody-immobilized plate in medium supplemented with IFN-gamma has a positive impact on DC maturation and may be optimal for eliciting an antigen-specific T-cell response without the need for CD4+ T-helper epitopes.
Similar articles
-
Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.J Surg Res. 2004 Jan;116(1):24-31. doi: 10.1016/j.jss.2003.09.003. J Surg Res. 2004. PMID: 14732346
-
Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow.Hum Immunol. 2004 Feb;65(2):93-103. doi: 10.1016/j.humimm.2003.11.002. Hum Immunol. 2004. PMID: 14969764
-
Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.Oncol Rep. 2007 Apr;17(4):895-902. Oncol Rep. 2007. PMID: 17342333
-
Dendritic cell gene therapy.Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. doi: 10.1016/s1055-3207(02)00027-3. Surg Oncol Clin N Am. 2002. PMID: 12487060 Review.
-
Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines.Crit Rev Immunol. 2001;21(1-3):157-78. Crit Rev Immunol. 2001. PMID: 11642602 Review.
Cited by
-
Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale.J Immunother. 2008 May;31(4):359-69. doi: 10.1097/CJI.0b013e318165f5d2. J Immunother. 2008. PMID: 18391760 Free PMC article.
-
Suppression of antigen-specific CD4+ T cell activation by SRA/CD204 through reducing the immunostimulatory capability of antigen-presenting cell.J Mol Med (Berl). 2012 Apr;90(4):413-26. doi: 10.1007/s00109-011-0828-1. Epub 2011 Nov 15. J Mol Med (Berl). 2012. PMID: 22083206 Free PMC article.
-
An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer.Cancer Immunol Immunother. 2007 Dec;56(12):1967-77. doi: 10.1007/s00262-007-0341-0. Epub 2007 Jun 13. Cancer Immunol Immunother. 2007. PMID: 17564704 Free PMC article.
-
Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease.Cancer Immunol Immunother. 2012 Nov;61(11):1929-39. doi: 10.1007/s00262-012-1252-2. Epub 2012 Apr 5. Cancer Immunol Immunother. 2012. PMID: 22476408 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials